Lifitegrast, sold under the brand name Xiidra (/ˈzaɪdrə/[2]), is a medication for the treatment of signs and symptoms of dry eye, a syndrome called keratoconjunctivitis sicca. Lifitegrast reduces inflammation by inhibiting inflammatory cell binding.[3] It is often used in conjunction with ciclosporin (Ikervis, Restasis, or Cequa) for dry eye treatment including meibomian gland dysfunction and inflammatory dry eye.
^"Eye health". Health Canada. 9 May 2018. Retrieved 13 April 2024.
^"Patient information: Xiidra® (ZYE-druh) (lifitegrast ophthalmic solution) 5% for topical ophthalmic use" (PDF). Novartis. June 2020. Retrieved 5 February 2021.
^Cite error: The named reference Tauber was invoked but never defined (see the help page).
Lifitegrast, sold under the brand name Xiidra (/ˈzaɪdrə/), is a medication for the treatment of signs and symptoms of dry eye, a syndrome called keratoconjunctivitis...
shampoo, or emptying ("expression") of the gland by a professional. Lifitegrast and Restasis are topical medication commonly used to control the inflammation...
cleanser, or emptying ("expression") of the gland by a professional. Lifitegrast and Restasis are topical medication commonly used to control the inflammation...
conjunctiva, rather than by directly stimulating the lacrimal glands. Lifitegrast was approved by the US FDA for the treatment of the condition in 2016...
Global Information
